Kalaris Therapeutics (NASDAQ:KLRS) Downgraded to Sell Rating by Wall Street Zen

Kalaris Therapeutics (NASDAQ:KLRS) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Friday.

Several other research analysts also recently weighed in on the company. Citigroup reaffirmed an “outperform” rating on shares of Kalaris Therapeutics in a research note on Thursday, December 18th. Citizens Jmp started coverage on shares of Kalaris Therapeutics in a report on Monday, November 3rd. They issued a “market outperform” rating and a $20.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Kalaris Therapeutics in a research report on Monday, December 29th. Finally, Chardan Capital started coverage on shares of Kalaris Therapeutics in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $19.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Kalaris Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Kalaris Therapeutics Stock Up 0.2%

KLRS stock opened at $9.80 on Friday. Kalaris Therapeutics has a 52-week low of $2.14 and a 52-week high of $12.90. The firm has a market cap of $183.26 million, a P/E ratio of -2.60 and a beta of -0.09. The company’s 50-day simple moving average is $8.13 and its 200-day simple moving average is $5.45.

Kalaris Therapeutics (NASDAQ:KLRS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.02.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Johnson Financial Group Inc. acquired a new position in Kalaris Therapeutics during the third quarter worth $58,000. Bridgeway Capital Management LLC acquired a new position in shares of Kalaris Therapeutics during the 3rd quarter valued at about $130,000. XTX Topco Ltd acquired a new position in shares of Kalaris Therapeutics during the 2nd quarter valued at about $65,000. Fortis Capital Advisors LLC purchased a new stake in shares of Kalaris Therapeutics in the third quarter valued at about $231,000. Finally, Belpointe Asset Management LLC acquired a new stake in Kalaris Therapeutics during the third quarter worth about $231,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.